New, affordable GLP-1 access for Medicare beneficiaries creates an opening for marketers to address seniors’ specific weight loss needs.
RevMed’s newly approved drug nearly doubles median survival in Stage 4 pancreatic cancer, showing that a less-established biotech can succeed where larger drugmakers have struggled.
11% of US adults currently use a GLP-1 medication, up from just 3% two years earlier, according to a July report from Gallup.
As employer health costs climb, reduced coverage for weight loss drugs will expand the self-pay GLP-1 market and intensify price competition among drugmakers.
Ecommerce plays a bigger role in purchasing health products than in discovery of them, giving brands an opportunity to convert in-store trial into online demand.
Brand and side-effect questions prompt longer-than-average chats, raising the value of comprehensive information as consumers weigh treatments.
Their new FDA-cleared test could help identify more Alzheimer’s patients and bring detection out of the specialists' office and into routine primary care.
Tech advocates see AI autonomy in medicine, but doctors’ safety, liability, and control concerns will stand in the way.
Consumers budget for weight loss as they cut spending elsewhere. Gyms, drugmakers, and supplement brands can build on that commitment with services supporting long-term health goals.
Drug price negotiations helped lower overall prices, but many patients still don't feel savings at the counter.
Consumers want simpler snack labels, but not at the sacrifice of taste and quality.
Drug pricing and TrumpRx questions eat into valuable doctor time. Drugmakers need to guide consumers to the right Rx resources.
Investors value AI-powered consumer health tech that turns biometric data into actionable guidance, but proprietary data and proven outcomes will set rivals apart.
Premium ice cream products were a bright spot in falling US ice cream sales—wellness-centric consumers are still willing to spend on higher-quality treats.
Their melanoma trial results could pave the way for treatments that are tailored to individual patients’ tumors.
Whoop will offer advanced lab testing to more non-members, risking a low-margin standalone business if they don’t convert to wearable customers.
How weight loss brands get rated on quality, price, and customer experience is ultimately what could win patients over.
It’s testing whether its brand will be a reliable enough selling point in a sea of senior-focused insurance options.
Protein-focused RXBAR and Quest top their category in EMARKETER’s inaugural US Food and Beverage AI Visibility Index, giving them an edge over general nutrition brands in a high-demand category.
A new AI-assisted tool tracks insulin resistance trends, giving users another way to monitor metabolic health.